An observational study in Atrial Fibrillation, Renal Insufficiency and Cardioversion, sponsored by Hadassah Medical Organization. Status unknown at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-07.
Sponsored by Hadassah Medical Organization · Observational
Atrial fibrillation is a common arrhythmia which requires electrical cardioversion in many patients in order to regain sinus rhythm. In a previous retrospective study a complication of acute renal failure was found in 17% of the patients after cardioversion.(The incidence and prognosis of renal dysfunction following cardioversion of atrial fibrillation. Helman Y,...Gilon D et al:Cardiology 2013;124(3);184-9.) Another complication previously described after cardioversion is pulmonary edema.
In this prospective study the investigators aim to evaluate the risk of acute renal failure post cardioversion. In addition the investigators would like to evaluate hemodynamic changes, fluid balance and sodium levels in patients post cardioversion as a potential mechanism for both acute renal failure and pulmonary edema post cardioversion. In order to assess hemodynamic changes the investigators will use a non-invasive FDA approved device called NICaS (Non-Invasive Cardiac System). This system calculates cardiac output, cardiac index and peripheral vascular resistance in a non-invasive, fast and accurate way.
1,995 studies on the registry are indexed under Renal Insufficiency; 173 are open to participants now.
This study's planned enrollment of 150 is close to the median of 149 across 394 observational studies indexed under Renal Insufficiency.
Browse Renal Insufficiency studies →Hadassah Medical Organization is the lead sponsor of 659 studies on the registry; 54 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients with new onset atrial fibrillation. Meaning less than three days.
Exclusion Criteria:
All comers with Atrial fibrillation
Other: Electrical atrial fibrillation Cardioversion · Other: Cardioversion
Electrical cardioversion for patients admitted for Atrial Fibrillation
Also known as: Cardioversion
Electrical cardioversion for patients admitted for Atrial Fibrillation
Renal dysfunction
Creatinine Clearance less 25 percent.
Time frame: Short term - One month
Mortality
Death
Time frame: One year
Plan to share: No
This study is status unknown, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hadassah Medical Organization